Therapy Name | Rimiducid |
Therapy Description |
Rimiducid is a tacrolimus analogue drug that contains an analogue of FKBP12, which allows homodimerization of genetically engineered receptors containing an FKBP12 binding domain, thereby, inducing apoptosis when necessary (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Rimiducid | AP1903 | Rimiducid is a tacrolimus analogue drug that contains an analogue of FKBP12, which allows homodimerization of genetically engineered receptors containing an FKBP12 binding domain, thereby, inducing apoptosis when necessary (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status |
---|---|---|---|---|
NCT02743611 | Phase I | Rimiducid BPX-701 | Dose Finding Study Evaluating Safety and Feasibility in Patients With Relapsed or Refractory Myeloid Neoplasms | Recruiting |
NCT03741127 | Phase I | Rimiducid | Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101 | Enrolling by invitation |
NCT02065869 | Phase Ib/II | BPX-501 Rimiducid | Safety Study of Gene Modified Donor T-cells Following TCR Alpha Beta Depleted Stem Cell Transplant | Active, not recruiting |
NCT01744223 | Phase Ib/II | Rimiducid BPX-501 | Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant | Active, not recruiting |
NCT02477878 | Phase I | BPX-601 Rimiducid | Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant | Active, not recruiting |
NCT02792114 | Phase I | Rimiducid Mesothelin CAR-T cells Cyclophosphamide | T-Cell Therapy for Advanced Breast Cancer | Recruiting |
NCT02786485 | Phase I | Rimiducid BPX-501 | Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT | Withdrawn |
NCT02487459 | Phase I | BPX-501 Rimiducid | Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies | Withdrawn |